{"createdAt":"8/2/2020, 2:09:27 PM","timestamp":1596391767326,"Company ID number":"363","DMX_ISSUER_NAME":"Aier Eye Hospital Group Co., Ltd.","DMX_ISSUER_ID":"IID000000002453496","Country of Classification":"CHINA","name":"Aier Eye Hospital Group Co Ltd ","code":"300015","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"爱尔眼科医院集团股份有限公司_陈邦","group":"board","name":"陈邦","title":"董事长,董事","isMale":true,"age":"55","degree":"硕士","salary":"105.7万","stockAmount":"6.593亿","description":"陈邦先生,1965年9月出生,硕士,湖南大学兼职MBA导师、爱尔眼科医院集团股份有限公司创始人,历任长沙爱尔眼科医院副董事长、长沙爱尔眼科医院集团副董事长、爱尔眼科医院集团董事长。现任爱尔医疗投资集团有限公司董事长、爱尔眼科医院集团股份有限公司董事长。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_李力","group":"board","name":"李力","title":"副董事长,董事","isMale":true,"age":"55","degree":"","salary":"105.7万","stockAmount":"1.432亿","description":"李力先生,1965年9月出生,历任长沙爱尔眼科医院董事长兼总经理、长沙爱尔眼科医院集团董事长兼总经理、爱尔眼科医院集团董事兼总经理。现任爱尔眼科医院集团股份有限公司副董事长、总经理。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_吴士君","group":"board","name":"吴士君","title":"董事","isMale":true,"age":"48","degree":"博士","salary":"92.00万","stockAmount":"51.68万","description":"吴士君先生,1972年10月出生,经济学博士,先后就职于中共上海市委、东方国际集团及证券行业,2004年11月加入爱尔眼科医院集团,现任爱尔眼科医院集团股份有限公司董事、副总经理兼董事会秘书、第十届深圳证券交易所上市委员会委员。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_韩忠","group":"board","name":"韩忠","title":"董事","isMale":true,"age":"55","degree":"本科","salary":"78.42万","stockAmount":"490.3万","description":"韩忠先生,1965年6月出生,中共党员,本科,注册会计师,历任湖南海联房产公司财务部经理、湖南省建设银行直属支行信贷部部长和会计部部长、长沙爱尔眼科医院董事、爱尔眼科医院集团财务总监、董事会秘书。现任爱尔眼科医院集团股份有限公司董事、副总经理、鄂豫大区CEO。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_陈收","group":"board","name":"陈收","title":"独立董事","isMale":true,"age":"64","degree":"博士","salary":"5000","stockAmount":"-","description":"陈收先生,1956年11月出生,中共党员,博士研究生,教授。历任湖南大学国际商学院、工商管理学院副院长、院长,湖南大学校长助理、副校长。现任湖南大学工商管理学院教授。","lastUpdated":"2019-11-28"},{"id":"爱尔眼科医院集团股份有限公司_郑远民","group":"board","name":"郑远民","title":"独立董事","isMale":true,"age":"54","degree":"博士","salary":"6.000万","stockAmount":"-","description":"郑远民先生,1966年6月出生,博士研究生,中国社会科学院法学研究所民商法博士后,教授、博士生导师。历任湖南大学法学院副教授、硕士生导师,法学院副院长,网络法中心主任。现任湖南师范大学法学院教授、博士生导师,《时代法学》编辑部主任,爱尔眼科医院集团股份有限公司独立董事。","lastUpdated":"2019-11-28"},{"id":"爱尔眼科医院集团股份有限公司_郭月梅","group":"board","name":"郭月梅","title":"独立董事","isMale":false,"age":"55","degree":"博士","salary":"5000","stockAmount":"-","description":"郭月梅女士,1965年11月出生,澳大利亚莫纳什大学税法博士,高级会计师,澳大利亚注册会计师。1988年8月至2004年1月任湖北省黄石市财政局外经科科长,2004年1月至今于中南财经政法大学任教,现任财政税务学院教授、博士生导师,武汉市武昌区人大常委、财经委委员,兼任中国财政学会理事、澳大利亚税收协会理事、湖北省财政学会理事等;2019年9月起任楚天高速公司独立董事。","lastUpdated":"2019-11-28"},{"id":"爱尔眼科医院集团股份有限公司_宁俊萍","group":"supervisoryCommittee","name":"宁俊萍","title":"监事会主席","isMale":false,"age":"42","degree":"本科","salary":"--","stockAmount":"-","description":"宁俊萍女士,1978年9月出生,本科学历。高级会计师、注册会计师。历任湖南九旺医药有限公司财务会计、湖南安邦制药有限公司财务部长、湖南湘雅制药有限公司财务经理、中浩建设股份有限公司财务经理、长沙高新医院股份有限公司财务经理,现任爱尔眼科医院集团股份有限公司财务中心税收管理部主任。","lastUpdated":"2020-04-14"},{"id":"爱尔眼科医院集团股份有限公司_曹琴琴","group":"supervisoryCommittee","name":"曹琴琴","title":"监事","isMale":false,"age":"33","degree":"本科","salary":"1250","stockAmount":"-","description":"曹琴琴女士,1987年10月生,毕业于中南林业科技大学会计学专业,管理学学士,中级会计师。曾任职于中国银行德雅路支行,湖南德力通电梯有限公司会计。现任爱尔医疗投资集团有限公司会计主管。","lastUpdated":"2019-11-28"},{"id":"爱尔眼科医院集团股份有限公司_李娴","group":"supervisoryCommittee","name":"李娴","title":"监事","isMale":false,"age":"24","degree":"本科","salary":"5300","stockAmount":"-","description":"李娴女士,出生于1996年7月,本科学历,会计从业资格证,现任职于爱尔眼科医院集团股份有限公司财务部。","lastUpdated":"2019-11-28"},{"id":"爱尔眼科医院集团股份有限公司_李力","group":"manager","name":"李力","title":"总经理","isMale":true,"age":"55","degree":"","salary":"105.7万","stockAmount":"1.432亿","description":"李力先生,1965年9月出生,历任长沙爱尔眼科医院董事长兼总经理、长沙爱尔眼科医院集团董事长兼总经理、爱尔眼科医院集团董事兼总经理。现任爱尔眼科医院集团股份有限公司副董事长、总经理。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_吴士君","group":"manager","name":"吴士君","title":"董事会秘书,副总经理","isMale":true,"age":"48","degree":"博士","salary":"92.00万","stockAmount":"51.68万","description":"吴士君先生,1972年10月出生,经济学博士,先后就职于中共上海市委、东方国际集团及证券行业,2004年11月加入爱尔眼科医院集团,现任爱尔眼科医院集团股份有限公司董事、副总经理兼董事会秘书、第十届深圳证券交易所上市委员会委员。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_韩忠","group":"manager","name":"韩忠","title":"副总经理","isMale":true,"age":"55","degree":"本科","salary":"78.42万","stockAmount":"490.3万","description":"韩忠先生,1965年6月出生,中共党员,本科,注册会计师,历任湖南海联房产公司财务部经理、湖南省建设银行直属支行信贷部部长和会计部部长、长沙爱尔眼科医院董事、爱尔眼科医院集团财务总监、董事会秘书。现任爱尔眼科医院集团股份有限公司董事、副总经理、鄂豫大区CEO。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_刘多元","group":"manager","name":"刘多元","title":"副总经理,财务总监","isMale":true,"age":"58","degree":"本科","salary":"67.46万","stockAmount":"145.8万","description":"刘多元先生,1962年4月出生,本科,会计师、注册会计师,历任衡阳县供销联社财务科长、湖南宏大空调有限公司(中港合资)财务部长、湖南潇湘会计师事务所审计部主任、爱尔眼科集团财务副总监。现任爱尔眼科医院集团股份有限公司副总经理兼财务总监。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_李爱明","group":"manager","name":"李爱明","title":"副总经理","isMale":true,"age":"50","degree":"本科","salary":"73.78万","stockAmount":"129.9万","description":"李爱明先生,1970年4月出生,本科,历任中荷合资常德达门船舶有限公司经理助理、湖南省回春堂制药厂销售中心市场总监、长沙爱尔眼科医院CEO、武汉爱尔眼科医院CEO。现任爱尔眼科医院集团股份有限公司副总经理。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_唐仕波","group":"manager","name":"唐仕波","title":"副总经理","isMale":true,"age":"59","degree":"博士","salary":"188.0万","stockAmount":"48.24万","description":"唐仕波先生,1961年4月出生,教育部二级教授,博士生导师,国家杰出青年基金获得者,国务院特殊津贴获得者,德国洪堡基金获得者,卫生部有突出贡献中青年专家,千百十工程国家级学科带头人培养对象,卫生部德育先进工作者,现任国家眼科学重点实验室玻璃体视网膜实验室主任、中华眼科学会眼底病学组副组长、亚太玻璃体视网膜学会理事、《中华眼底病杂志》、《眼科学报》副主编及《中华眼科杂志》、《中华眼视光杂志》、《中华实验眼科》等编委、《GraefesArchClinExpOphthalmol》、《APJO》编委。1992年,获德国慕尼黑大学博士学位,随后在德国Regensburg大学从事博士后研究;1999年-2012年,任中山大学中山眼科中心副主任、眼科医院副院长;现任爱尔眼科医院集团股份有限公司副总经理、总院长。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_杨智宽","group":"manager","name":"杨智宽","title":"副总经理","isMale":true,"age":"56","degree":"博士","salary":"103.0万","stockAmount":"67.83万","description":"杨智宽先生,1964年12月出生,博士学历、博士研究生导师,历任中山眼科中心视光学系副主任及验配中心副总经理、复旦大学眼耳鼻喉医院汾阳视听公司总经理、中南大学爱尔眼科学院副院长。现任爱尔眼科集团视光及小儿眼科事业部总监、湖南爱尔视光研究所所长、爱尔眼科医院集团视光学组组长、爱尔眼科医院集团学术委员会副主任委员。社会兼职:中华医学会眼科学分会视光学组副组长、中国医师协会眼科医师分会视光专委会副主任委员、国家卫计委产业管理协会视光分会副会长、中国医促会视觉健康分会副主任委员、湖南省视光学会会长、卫计委近视眼重点实验室学术委员会委员、中华眼视光杂志及视觉科学杂志编委、国家自然科学基金评审专家、教育部学位中心博士研究生论文评审专家、南昌大学及温州医科大学研究生兼职导师。现任爱尔眼科医院集团股份有限公司副总经理兼视光事业部总监。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_王丽华","group":"manager","name":"王丽华","title":"副总经理","isMale":false,"age":"46","degree":"本科","salary":"63.66万","stockAmount":"69.33万","description":"王丽华女士,1974年5月出生,本科,历任爱尔眼科集团总裁办副主任、人力资源部经理。现任爱尔眼科医院集团股份有限公司副总经理兼人力资源中心总监。","lastUpdated":"2019-12-02"},{"id":"爱尔眼科医院集团股份有限公司_冯珺","group":"manager","name":"冯珺","title":"副总经理","isMale":false,"age":"41","degree":"硕士","salary":"--","stockAmount":"-","description":"冯珺女士,1979年7月出生,硕士,湖南大学MBA,现任爱尔眼科医院集团股份有限公司屈光事业部总监。","lastUpdated":"2020-04-14"}],"companyName":"爱尔眼科医院集团股份有限公司","province":"湖南省","englishName":"Aier Eye Hospital Group Co Ltd","industry":"医药生物 — 医疗服务Ⅱ","website":"www.aierchina.com","mainBusiness":"眼科医疗服务与视光医疗服务","productsName":["屈光项目","白内障项目","眼前段项目","眼后段项目","视光服务项目"],"actualController":"陈邦","actualControllerSharePercentage":"44.38%","registeredCapital":"41.22亿元","employeeAmount":"18241","phone":"86-0731-85136739","location":"湖南省长沙市芙蓉区芙蓉中路二段198号新世纪大厦4楼","chineseDescription":"爱尔眼科医院集团股份有限公司是一家眼科医疗机构,公司主要为向患者提供各种眼科疾病的诊断、治疗及医学验光配镜等眼科医疗服务。公司主办了2019国际视网膜高峰论坛、国际屈光论坛、智慧医疗高峰论坛等学术会议，发布《爱尔眼科中国国人眼底病变状况大数据报告》，成功获得2023年第19届世界近视眼大会的主办权。","foundedDate":"2003-01-24","goPublicDate":"2009-10-30","companyHistory":"爱尔眼科医院集团股份有限公司（以下简称“公司”或“本公司”，原名称“长沙爱尔眼科医院有限公司”、“长沙爱尔眼科医院集团有限公司”、“爱尔眼科医院集团有限公司”），系经长沙市工商行政管理局批准，由自然人陈邦、李力共同以实物资产出资，于2003年1月24日成立。\n　　2007年12月，经公司2007年第十次股东会决议，公司由原有股东作为发起人，以截至2007年9月30日经审计的净资产，按1.27:1的比例折股，整体变更为股份有限公司，变更后的股本总额为100,000,000元。\n　　根据公司2009年第二次临时股东大会决议和修改后章程的规定，并经中国证券监督管理委员会“证监许可［2009］1008”号文核准，2009年10月，公司采用网下向配售对象询价配售和网上向社会公众投资者定价发行相结合的方式首次向社会公开发行人民币普通股（A股）3,350万股，发行后公司总股本为13,350万股。经深圳证券交易所深证上[2009]124号文同意，公司公开发行的人民币普通股3,350万股于2009年10月30日在深圳证券交易所挂牌上市。\n　　根据公司2009年度股东大会决议，公司以2009年12月31日总股本133,500,000股为基数，以资本公积向全体股东每10股转增10股，共转增133,500,000股，转增后公司总股本为267,000,000股。该次转增股本于2010年6月完成工商变更登记手续。\n　　根据公司2011年第一次临时股东大会决议，公司以2011年6月30日总股本267,000,000股为基数，以资本公积向全体股东每10股转增6股，共转增160,200,000股，转增后公司总股本为427,200,000股。该次转增股本于2011年10月完成工商变更登记手续。\n　　根据公司2013年第一次临时股东大会决议，公司于2013年向首期249名激励对象发行限制性股票5,446,500股，增加股本5,446,500股。\n　　2014年1月公司将预留限制性股票授予62名激励对象，增加股本625,000股，公司均已办理了工商变更登记手续。\n　　2014年1月公司召开第三届董事会第五次会议，审议通过了《关于回购注销部分已授予限制性股票的议案》，同意将5名离职激励对象已获授但未解锁的全部限性股票60,000股进行回购注销。公司总股本由433,271,500股减至433,211,500股。该次回购注销股本已于2014年5月完成工商变更登记手续。\n　　根据公司2013年度股东大会决议、第三届董事会第八次会议决议和修改后的章程规定，公司以资本公积转增股本216,635,711股；根据公司2013年第一次临时股东大会决议、第三届董事会第十二次会议决议和修改后的章程规定，公司激励对象第二期行权并缴纳增资款，增加注册资本2,147,031股。以上两项合计增加股本218,782,742股，公司总股本由433,211,500股增至651,994,242股，此次变更已于2014年9月完成工商变更登记手续。\n　　2014年7月至12月，公司激励对象第三期行权并缴纳增资款，增加股本2,316,816股，增资后公司总股本由651,994,242股增至654,311,058股，此次变更于2015年7月完成工商变更登记手续。\n　　2015年1月至12月期间，公司激励对象第三、四期（部分）行权并缴纳增资款，新增股本4,012,012股，其中新增880,720股公司已于2015年完成工商变更手续，另增加3,131,292股的已于2016年6月完成工商变更登记手续。\n　　2015年3月19日，公司召开第三届董事会第二十三次会议，审议通过了《关于回购注销部分已授予限制性股票的议案》，同意将12人离职激励进行回购注销，本次回购注销限制性股票150,660股，该次回购注销于2015年7月完成工商变更登记手续。根据2014年度股东大会决议、第三届董事会第二十四次会议决议公司以资本公积转增股本327,387,782股。此次转增于2015年7月已完成工商变更登记手续。\n　　2016年1月至12月期间，公司激励对象第四（部分）、五期（部分）行权并缴纳增资款，新增股本4,735,559.00股，其中新增1,595,037.00股已于2016年7月1日办理了工商变更手续，另增加3,140,522.00股的工商手续正在办理之中。\n　　2016年3月10日，公司第三届董事会第四十次会议审议通过了《关于回购注销部分已授予限制性股票的议案》。公司原激励对象罗卫兵、秦应祥、陶津华、陈红兵4人因离职已不符合激励条件，公司董事会同意回购注销其已获授但未解锁的全部限制性股票34,815股,该次回购注销于2016年7月1日完成工商变更登记手续。\n　　根据公司2015年度股东大会决议，公司于2016年6月8日公司向首期1557名激励对象发行限制性股票2,005.9万股，增加股本2,005.9万股。此次变更于2016年7月25日已完成工商变更登记手续。\n　　2017年1月至5月期间，公司激励对象第五期行权并缴纳增资款，新增股本1,585,807.00股，新增股本工商手续正在办理中。\n　　根据公司2016年度股东大会决议，公司以2016年12月31日总股本1,011,905,743股为基数，向全体股东每10股送红股5.00股，共转增505,952,871.00股，转增后公司总股本为1,517,858,614.00股，新增股本工商手续正在办理中。\n　　2017年5月公司将预留限制性股票授予322名激励对象，增加股本2,863,150.00股，此次变更工商手续正在办理中。\n　　截至2017年6月30日，本公司注册资本为人民币1,011,905,743.00元，实收资本为人民币1,520,721,764.00元。\n　　根据2015年度股东大会授权，2017年5月23日，公司第四届董事会第十二次会议审议通过《关于向激励对象授予预留限制性股票的议案》，公司于2017年5月23日将预留限制性股票授予322名激励对象，增加股本2,863,150股。此次变更于2017年9月6日已完成工商变更登记手续。\n　　2017年6月12日，公司第四届董事会第十四次会议审议通过了《关于回购注销部分已授予限制性股票的议案》。公司原激励对象杨禹志、许伟、陈佩琼、莫国才等42人因离职已不符合激励条件，公司董事会同意回购注销其已获授但未解锁的全部限制性股票706,800股。该次回购注销于2017年9月27日完成工商变更登记手续。\n　　根据公司2016年第二次临时股东大会会议决议，并经中国证券监督管理委员会“证监许可[2017]1999”号文核准，2017年12月，公司非公开发行62,328,663股新股，增加股本62,328,663股。此次变更于2018年3月21日已完成工商变更登记手续。\n　　截至2017年12月31日，本公司注册资本为人民币1,520,014,964.00元，实收资本为人民币1,585,984,466.00元。\n　　2018年1月10日，公司第四届董事会第二十三次会议审议通过了《关于变更注册资本、修订公司章程并办理工商变更登记的议案》。根据会议决议，公司于2018年3月21日已完成工商变更登记手续，取得了湖南省工商行政管理局换发的《营业执照》，统一社会信用代码：91430000745928604G，注册资本由1,520,014,964元变更为1,582,343,627元。\n　　2018年6月28日，公司第四届董事会第三十二次会议审议通过了《关于变更注册资本、修订公司章程并办理工商变更登记的议案》。鉴于公司股票期权激励计划第六个行权期已于2018年5月5日结束，股票期权激励对象在第六个行权期内共行权7,011,523份，行权结束后，公司注册资本将随之发生变动，由1,582,343,627元增至1,589,355,150元。根据公司2010年度股东大会授权，董事会决定在股票期权第六个行权期行权完毕后将及时办理增加注册资本、修订公司章程及工商变更登记等相关事宜。根据会议决议，公司及时办理了工商变更登记手续。\n　　2018年8月1日，公司取得了湖南省工商行政管理局换发的《营业执照》，统一社会信用代码：91430000745928604G，注册资本由1,582,343,627元变更为1,589,355,150元。\n　　2018年5月15日，公司2017年度股东大会审议通过《2017年度权益分配方案》，以公司2018年3月31日的总股本1,589,180,683股为基数，向全体股东每10股派发现金红利3.0元（含税），合计派发现金476,754,204.90元；同时，以2017年末公司资本公积金向全体股东每10股转增5股，合计转增794,590,342股。董事会审议权益分派预案后股本发生变动的，将按照分配总额不变的原则对分配比例进行调整。由于公司股权激励计划的股票期权行权，截至2018年5月16日公司总股本增至1,589,355,150股，因此，本公司2017年度权益分派方案为：以公司现有总股本1,589,355,150股为基数，向全体股东每10股派2.999671元人民币现金（含税），同时，以资本公积金向全体股东每10股转增4.999451股。分红前本公司总股本为1,589,355,150股，本次转增794,590,319股，分红后总股本增至2,383,945,469股。上述权益分配已于2018年5月24日实施，公司已于2018年8月17日已完成工商变更登记手续。\n　　2018年06月30日，本公司注册资本为人民币1,589,355,150.00元，实收资本为人民币2,383,945,469.00元。\n　　2019年5月21日，公司2018年度股东大会审议通过《2018年度权益分配方案》，以公司2019年3月31日的总股本2,383,945,469股为基数，向全体股东每10股派发现金红利2.0元（含税），合计派发现金476,676,029.60元；同时，以2018年末公司资本公积金向全体股东每10股转增3股，合计转增715,014,044股。分红前本公司总股本为2,383,945,469股，本次转增715,014,044股，分红后总股本增至3,098,394,192股。上述权益分配已于2019年6月5日实施，公司已于2019年7月22日已完成工商变更登记手续。\n　　截至2019年12月31日，本公司注册资本为人民币3,097,811,227.00元，实收资本为人民币3,097,811,227.00元。收起▲","shareholders":[{"organizationId":"T001995096","holderName":"爱尔医疗投资集团有限公司","totalShare":"11.71亿","sharePercentage":"37.81%"},{"organizationId":"","holderName":"陈邦","totalShare":"5.07亿","sharePercentage":"16.37%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"2.37亿","sharePercentage":"7.65%"},{"organizationId":"","holderName":"李力","totalShare":"1.10亿","sharePercentage":"3.56%"},{"organizationId":"","holderName":"郭宏伟","totalShare":"7387.42万","sharePercentage":"2.38%"},{"organizationId":"T000118219","holderName":"高瓴资本管理有限公司-HCM中国基金","totalShare":"4874.86万","sharePercentage":"1.57%"},{"organizationId":"","holderName":"TEMASEKFULLERTONALPHAPTELTD","totalShare":"3097.00万","sharePercentage":"1.00%"},{"organizationId":"","holderName":"中国银行股份有限公司-易方达中小盘混合型证券投资基金","totalShare":"2700.00万","sharePercentage":"0.87%"},{"organizationId":"","holderName":"安本标准投资管理(亚洲)有限公司-安本标准-中国A股股票基金","totalShare":"2416.08万","sharePercentage":"0.78%"},{"organizationId":"","holderName":"MERRILLLYNCHINTERNATIONAL","totalShare":"2366.81万","sharePercentage":"0.76%"}],"englishDescription":"Aier Eye Hospital Group Co.,Ltd. is a China-based ophthalmic medical institution. The Company is mainly engaged in ophthalmic diseases treatment, surgical services and medical optometry. The Company mainly provides corneal refractive surgery, cataract operation, anterior segment operation, posterior segment operation and optometry services. The Company mainly operates its business in domestic market, with Central China as its main market.","englishIndustry":"Healthcare Facilities","Price to earnings (ttm)":"121.25","Price to sales (ttm)":"19.89","Price to book (mrq)":"21.01","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"47.49","Lt debt to equity (mrq)":"26.76","Return on investment (ttm)":"14.51","Return on equity (ttm)":"10.31","Income statement":{"Revenue":"9,990.10","Total revenue":"9,990.10","Cost of revenue, total":"5,064.55","Gross profit":"4,925.55","Selling/general/admin. expenses, total":"2,369.93","Research & development":"140.75","Depreciation/amortization":"83.20","Interest exp.(inc.),net-operating, total":"(6.23)","Unusual expense (income)":"319.04","Other operating expenses, total":"0.93","Total operating expense":"7,972.18","Operating income":"2,017.93","Other, net":"(177.68)","Net income before taxes":"1,840.24","Provision for income taxes":"409.08","Net income after taxes":"1,431.16","Minority interest":"(52.24)","Net income before extra. items":"1,378.92","Net income":"1,378.92","Income available to com excl extraord":"1,378.92","Income available to com incl extraord":"1,378.92","Diluted net income":"1,378.92","Diluted weighted average shares":"3,097.81","Diluted eps excluding extraord items":"0.45","Dps - common stock primary issue":"0.12","Diluted normalized eps":"0.53","Gain (loss) on sale of assets":"(2.03)"},"Balance sheet":{"Cash":"4.88","Cash & equivalents":"1,835.30","Short term investments":"300.00","Cash and short term investments":"2,140.18","Accounts receivable - trade, net":"1,179.88","Total receivables, net":"1,399.18","Total inventory":"374.21","Prepaid expenses":"113.50","Total current assets":"4,027.08","Property/plant/equipment, total - gross":"4,028.70","Accumulated depreciation, total":"(1,811.67)","Property/plant/equipment, total - net":"2,217.03","Goodwill, net":"2,637.99","Intangibles, net":"555.05","Long term investments":"1,755.12","Other long term assets, total":"702.48","Total assets":"11,894.75","Accounts payable":"1,091.68","Accrued expenses":"431.51","Notes payable/short term debt":"683.83","Current port. of  lt debt/capital leases":"309.43","Other current liabilities, total":"362.20","Total current liabilities":"2,878.64","Long term debt":"1,635.71","Total long term debt":"1,635.71","Total debt":"2,628.96","Deferred income tax":"74.21","Minority interest":"428.69","Other liabilities, total":"283.46","Total liabilities":"5,300.71","Common stock, total":"3,097.81","Additional paid-in capital":"561.30","Retained earnings (accumulated deficit)":"3,023.83","Treasury stock - common":"(62.85)","Other equity, total":"(26.05)","Total equity":"6,594.04","Total liabilities & shareholders' equity":"11,894.75","Total common shares outstanding":"3,097.81","Tangible book value per share, common eq":"1.10","Other current assets, total":"402.43"},"Cash flow":{"Cash receipts":"9,829.86","Cash payments":"(3,154.70)","Cash taxes paid":"(565.63)","Changes in working capital":"(4,031.10)","Cash from operating activities":"2,078.43","Capital expenditures":"(745.63)","Other investing cash flow items, total":"(1,013.47)","Cash from investing activities":"(1,759.10)","Financing cash flow items":"(119.49)","Total cash dividends paid":"(514.10)","Issuance (retirement) of debt, net":"798.00","Cash from financing activities":"164.41","Foreign exchange effects":"4.13","Net change in cash":"487.88"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"45.30","52 Week High":"48.23","52 Week Low":"22.15","Pricing date":"","10 Day Average Trading Volume":"26.49","Market Capitalization":"186,713.70","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"546.60","Beta":"0.58","1 Day Price Change":"-0.04","13 Week Price Return (Daily)":"32.66","26 Week Price Return (Daily)":"47.22","5 Day Price Return (Daily)":"2.95","52 Week Price Return (Daily)":"94.74","Year To Date Price Return (Daily)":"48.86","Month to Date Price Return (Daily)":"4.26","Price Relative to S&P500 (4 Week)":"-4.51","Price Relative to S&P500 (13 Week)":"4.30","Price Relative to S&P500 (26 Week)":"15.31","Price Relative to S&P500 (52 Week)":"32.34","Price Relative to S&P500 (YTD)":"13.86"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.45","EPS excl. Extra Items (TTM)":"0.37","EPS Normalized (Annual)":"0.53","Revenue per Share (Annual)":"3.22","Revenue per Share (TTM)":"3.01","Book Value (Per Share Annual)":"2.13","Book Value (Per Share Quarterly)":"2.16","Tangible Book Value (Per Share Annual)":"1.10","Tangible Book Value (Per Share Quarterly)":"1.12","Cash Per Share (Per Share Annual)":"0.69","Cash Per Share (Per Share Quarterly)":"0.90","Cash Flow (Per Share Annual)":"0.58","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.12","Dividends (Per Share TTM)":"0.12","EBITD (Per Share TTM)":"0.64","EPS Basic excl. Extra Items (Annual)":"0.45","EPS Basic excl. Extra Items (TTM)":"0.37","EPS incl. Extra Items (Annual)":"0.45","EPS incl. Extra Items (TTM)":"0.37","Free Cash Flow (Per Share TTM)":"0.15","Dividend (Per Share 5Y)":"0.12"},"Valuation":{"P/E excl. Extra Items (Annual)":"101.77","P/E excl. Extra Items (TTM)":"121.25","P/E Normalized (Annual)":"86.25","Price to sales (Annual)":"18.69","Price to sales (TTM)":"19.89","Price to Tangible Book (Annual)":"54.90","Price to Tangible Book (Quarterly)":"54.01","Price to Free Cash Flow (Per Share Annual)":"228.06","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"394.24","Price to Book (Annual)":"21.28","Price to Book (Quarterly)":"21.01","P/E Basic excl. Extra Items (TTM)":"80.93","P/E excl. Extra Items High (TTM)":"81.08","P/E excl. Extra Items Low (TTM)":"38.95","P/E incl. Extra Items (TTM)":"121.25","Net Debt (Interim)":"397.03","Net Debt (Annual)":"488.78","Dividend Yield (5Y)":"0.79","Dividend Yield":"0.25","Current Dividend Yield (TTM)":"0.25"},"Financial Strength":{"Free Cash Flow (Annual)":"818.71","Current Ratio (Annual)":"1.40","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"24.81","Payout Ratio (Annual)":"33.70","Quick Ratio (Annual)":"1.27","Total Debt/Total Equity (Annual)":"39.87","Current EV/Free Cash Flow (Annual)":"352.34","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.42","Long Term Debt/Equity (Quarterly)":"26.76","Quick Ratio (Quarterly)":"1.32","Total Debt/Total Equity (Quarterly)":"47.49","Free Cash Flow (TTM)":"473.60","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"40.07"},"Margins":{"Gross Margin (Annual)":"49.30","Gross Margin (TTM)":"46.59","Net Profit Margin % (Annual)":"14.33","Net Profit Margin (TTM)":"12.62","Operating Margin (Annual)":"20.20","Operating Margin (TTM)":"18.11","Pretax Margin (TTM)":"15.98","Pretax Margin (Annual)":"18.42","Operating Margin (5Y)":"19.22","Pretax Margin (5Y)":"17.61","Free Operating Cash Flow/Revenue (5Y)":"5.26","Free Operating Cash Flow/Revenue (TTM)":"5.05","Gross Margin (5Y)":"47.44","Net Profit Margin (5Y)":"13.79"},"Management Effectiveness":{"Return on Assets (Annual)":"13.30","Return on Equity (TTM)":"10.31","Return on Average Equity (Annual)":"22.45","Return on Average equity (TTM)":"18.33","Return on Investment (Annual)":"18.01","Return on Investment (TTM)":"14.51","Return on Average Assets (5Y)":"12.68","Return on Average Equity (5Y)":"19.93","Return on Investment (5Y)":"16.89","Asset Turnover (Annual)":"0.93","Asset Turnover (TTM)":"0.82","Inventory Turnover (Annual)":"13.81","Inventory Turnover (TTM)":"14.75","Net Income/Employee (Annual)":"82,556.52","Net Income/Employee (TTM)":"64,949.02","Receivables Turnover (Annual)":"9.69","Receivables Turnover (TTM)":"8.83","Revenue/Employee (Annual)":"576,280.10","Revenue/Employee (TTM)":"514,616.80"},"Growth":{"Revenue Growth (Quarterly YoY)":"-26.86","Revenue Growth Rate (5Y)":"32.98","EPS Growth (Quarterly YoY)":"-73.41","EPS Growth (TTM YoY)":"5.15","EPS Growth Rate (5Y)":"32.81","Dividend Growth Rate (3Y)":"23.31","Revenue Growth (TTM YoY)":"10.35","Revenue Growth (Per Share 5Y)":"30.97","Revenue Growth Rate (3Y)":"35.67","EPS Growth Rate (3Y)":"32.28","Book Value Growth Rate (Per Share 5Y)":"24.89","Tangible Book Value Total Equity CAGR (5Y)":"14.69","Capital Spending growth rate 5 year":"33.38","EBITDA CAGR (5Y)":"38.81","EBITDA Interim CAGR (5Y)":"34.20","Free Operating Cash Flow CAGR (5Y)":"31.09","Total Debt CAGR (5Y)":"--","Net Profit Margin Growth Rate (5Y)":"1.92"},"Income Statement":{"Revenue (Annual)":"9,990.10","Revenue (TTM)":"9,387.13","EBITD (Annual)":"2,691.83","EBITD (TTM)":"1,980.35","Earnings Before Taxes (Annual)":"1,840.24","Earnings Before Taxes (TTM)":"1,499.99","Net Income to Common (Annual)":"1,378.92","Net Income to Common (TTM)":"1,159.77","Earnings Before Taxes Normalized (Annual)":"2,159.28","Net Income Available to Common Normalized (Annual)":"1,627.04","Diluted Normalized EPS excl. Extra Items (TTM)":"0.46"}}}